• DGLA-Induced Ferroptosis via ACSL4 in AML: Mechanistic Insig

  2026-05-25

  This study uncovers how exogenous dihomo-γ-linolenic acid (DGLA) induces ferroptosis in acute myeloid leukemia (AML) cells through ACSL4-mediated lipid metabolic reprogramming. These findings highlight a potential metabolic vulnerability in AML, suggesting new therapeutic strategies targeting ferroptosis pathways.

• SM-164: Precision IAP Antagonism and the New Era of Apoptosi

  2026-05-25

  Explore how SM-164, a potent bivalent Smac mimetic, is redefining apoptosis induction in tumor cells by leveraging new insights into regulated cell death mechanisms. This in-depth analysis uniquely connects molecular pharmacology with practical assay design for advanced cancer research.

• KR-12 (human) TFA: Molecular Engineering and Translational P

  2026-05-24

  Explore the multifaceted bioactivity and engineering of KR-12, the human antimicrobial peptide, with a focus on its design, copper-binding, and translational applications. This article provides a deep scientific perspective and expert guidance for researchers leveraging KR-12 in advanced antimicrobial, anti-biofilm, and immunomodulatory studies.

• A40926 Aglycone and Pseudoaglycones: Activity and Preparatio

  2026-05-23

  The referenced study systematically prepared and characterized aglycone and pseudoaglycone derivatives of A40926, a potent glycopeptide antibiotic precursor to dalbavancin. It revealed how specific structural modifications impact antibacterial activity, particularly against Gram-positive bacteria and Neisseria gonorrhoeae, providing valuable insights for antibiotic development and resistance research.

• Applied Workflows with ddATP: Precision DNA Termination Unlo

  2026-05-22

  Harness ddATP (2',3'-dideoxyadenosine triphosphate) as a chain-terminating nucleotide analog for unrivaled control in DNA synthesis assays. Discover how its unique properties streamline Sanger sequencing, DNA repair research, and advanced replication studies, backed by new mechanistic insights and troubleshooting strategies.

• Fumagillin as a Methionine Aminopeptidase-2 Inhibitor: Preci

  2026-05-22

  Explore the multifaceted research uses of Fumagillin as a potent methionine aminopeptidase-2 inhibitor, with a focus on advanced protocol considerations and translational insights that go beyond typical oncology or antiparasitic narratives.

• Baicalin and KEAP1-NRF2/HO-1 Pathway Modulation in Research

  2026-05-21

  Baicalin’s precise modulation of the KEAP1-NRF2/HO-1 and TGF-β1/p-Smad3 pathways is reshaping workflows in neuroplasticity and cancer research. This guide translates breakthrough findings and real-world troubleshooting insights into actionable protocols for scientists leveraging APExBIO’s high-purity Baicalin.

• Saquinavir as a Benchmark HIV Protease Inhibitor in Drug Res

  2026-05-21

  Saquinavir, a potent HIV protease inhibitor, enables high-precision modeling and permeability studies in antiretroviral drug research. This article demystifies advanced workflows, highlights troubleshooting strategies, and distills innovations from biomimetic chromatography, positioning APExBIO's Saquinavir as a gold-standard tool for HIV infection and translational research.

• LACTB Orchestrates Mitochondrial Remodeling to Promote Apopt

  2026-05-20

  This study reveals that the mitochondrial serine protease LACTB is a critical mediator of inner mitochondrial membrane remodeling during apoptosis, facilitating cytochrome c release and apoptotic cell death. The findings provide mechanistic insight into LACTB's tumor suppressor function and highlight new approaches for dissecting mitochondrial-dependent apoptosis in cancer and cell biology.

• Gepotidacin (GSK2140944): Optimizing Antibacterial Research

  2026-05-20

  Gepotidacin’s unique inhibition of bacterial type II topoisomerases unlocks new experimental strategies for antibiotic resistance research. This guide details workflow setup, protocol advances, and troubleshooting tactics for maximizing data quality with APExBIO’s Gepotidacin in cutting-edge antibacterial assays.

• THZ1: Redefining Covalent CDK7 Inhibition in T-ALL Research

  2026-05-19

  This article delivers a mechanistically-driven, strategic roadmap for translational researchers deploying THZ1—a potent, selective covalent CDK7 inhibitor—in cancer biology, with a focus on overcoming resistance in T-ALL. Integrating structural insights, comparative analysis, and practical workflow guidance, we chart the future of transcription regulation inhibition and precision oncology.

• Deferasirox Fe3+ Chelate: Bridging Iron Metabolism and Lysos

  2026-05-19

  This article advances the strategic dialogue on Deferasirox Fe3+ chelate by integrating recent mechanistic findings on lysosomal iron handling, metabolic adaptation, and cell death. Building on both foundational and contemporary studies, it offers translational researchers actionable experimental guidance, competitive insight, and a forward-looking outlook for iron overload and metabolic stress models.

• A40926: Novel Glycopeptide Antibiotic with Anti-Neisseria Ac

  2026-05-18

  This paper reports the discovery and characterization of A40926, a glycopeptide antibiotic produced by Actinomadura with notable activity against both Gram-positive bacteria and Neisseria gonorrhoeae. The study details its unique molecular features, rapid bactericidal effects, and pharmacokinetic advantages, highlighting its significance for antibiotic development and Gram-positive infection research.

• Dextromethorphan Hydrobromide: Reliable NMDA Antagonist for

  2026-05-18

  This article examines practical laboratory challenges in neuroprotection assays and explains how Dextromethorphan hydrobromide (SKU B3478) delivers reproducible results as an NMDA receptor antagonist. Through scenario-driven Q&A, we compare vendor quality, optimize protocols, and contextualize SKU B3478’s advantages for biomedical workflows.

• Gap19: Selective Connexin 43 Hemichannel Blocker for Neuropr

  2026-05-17

  Gap19 is a selective connexin 43 hemichannel blocker with validated efficacy in neuroprotection and immune modulation. It inhibits Cx43 hemichannel-mediated ATP release in astrocytes and attenuates M1 macrophage polarization via the Cx43/NF-κB pathway. Gap19 demonstrates translational value in ischemic brain injury models.

452 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page